Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 37,869 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

37,869 Papers indexed
963 Papers AI scored
37,869 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

37869 results
B
[Safety and efficacy of mitoxantrone liposome combined chemotherapy in the treatment of mixed phenotype acute leukemia].
PMID 40059684 Published: 2025-01-14 Ingested: 2026-08-02 12:03 AM Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
AI -
Base 73.0
Rank 73.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 100.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 100.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Development of a clinical decision support tool for Primary care Management of lower Urinary tract Symptoms in men: the PriMUS study.
PMID 39895567 Published: 2025-01-01 Ingested: 2026-08-02 12:03 AM Health technology assessment (Winchester, England)
AI -
Base 73.0
Rank 73.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.0/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 73.0
Rank 73.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.0/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

B
Targeted immunotherapy in the treatment of childhood and adolescent classic Hodgkin lymphoma.
PMID 39820376 Published: 2024-12-01 Ingested: 2026-08-02 12:03 AM Clinical advances in hematology & oncology : H&O
AI -
Base 73.0
Rank 73.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 100.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Hair Straightener Use in Relation to Prevalent and Incident Fibroids in the Sister Study with a Focus on Black Women.
PMID 39808082 Published: 2025-01-14 Ingested: 2026-08-02 12:03 AM Environmental health perspectives
AI -
Base 73.0
Rank 73.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.0/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 10.0; sample size: 90.0; recency: 90.0; abstract quality: 100.0.

B
Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.
PMID 39804528 Published: 2025-01-13 Ingested: 2026-08-02 12:03 AM Molecular neurobiology
AI -
Base 73.0
Rank 73.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 100.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy.
PMID 39708175 Published: 2024-12-21 Ingested: 2026-08-02 12:03 AM Cancer immunology, immunotherapy : CII
AI -
Base 73.0
Rank 73.0
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.0/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 100.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

Previous
Page 438 of 3156
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic